: As nitrogen-containing five-membered heterocyclic structural units, the substituted pyrazole derivatives have broad spectrum of pharmacological activities, especially 4,5-dihydro-1H-pyrazoles that also commonly known as 2-pyrazolines. Since 2010, considerable studies have been found that the 2-pyrazoline derivatives possess potent anticancer activities. In present review, it covers the pyrazoline derivatives reported by literatures from 2010 till date (2010-2019). This review aims to establish the relationship between the anticancer activities variation and different substituents introduced into 2-pyrazoline core, which could provide important pharmacophore clues for the discovery of new anticancer agents that containing 2-pyrazoline scaffold.

No abstract

No abstract

No abstract

Background: Almost 50% of metastatic melanomas harbor BRAF mutations. Since 2011, BRAF inhibitors have exhibited striking clinical benefits in BRAF-mutant melanoma patients. Unfortunately, their therapeutic effects are often temporary. The resistance mechanisms vary and can be broadly classified as MAPK reactivationdependent and -independent. Elucidation of these resistance mechanisms provides new insights into strategies for overcoming resistance. Indeed, several alternative treatment strategies, including changes in the mode of administration, combinations of BRAF and MEK inhibitors, and immunotherapy have been verified as beneficial to BRAF inhibitor-resistant melanoma patients. Prospect: In this review, we discuss promising strategies for overcoming drug resistance and highlight the prospects for discovering strategies to counteract BRAF inhibitor resistance.